Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 study of CERC-301 in patients with neurogenic Orthostatic Hypotension (nOH) associated with Parkinson's disease.

Trial Profile

Phase 1 study of CERC-301 in patients with neurogenic Orthostatic Hypotension (nOH) associated with Parkinson's disease.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jul 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rislenemdaz (Primary)
  • Indications Orthostatic hypotension; Parkinson's disease
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Sponsors Cerecor
  • Most Recent Events

    • 01 Jul 2019 Final Results presented in a Cerecor Inc Media Release.
    • 01 Jul 2019 Status changed from active, no longer recruiting to completed according to a Cerecor Inc Media Release.
    • 01 Jul 2019 According to a Cerecor Inc media release, the study enrolled 19 patients with nOH associated with Parkinson's disease of which 14 were randomized. Enrollment was closed following the positive interim results seen in April 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top